Nathanael Gray

Citado por

	Total	Desde 2017
Citas	69616	39683
Índice h	127	97
Índice i10	478	429

9000

4500

2250

6750

20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022239 299 374 485 500 541 598 645 699 1040 1607 2245 2949 3622 3879 4566 4905 5335 5719 6332 7827 8787 5635

Acceso público

Ver todo

347 artículos

10 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Richard YoungProfessor of Biology, MITDirección de correo verificada de wi.mit.edu
Ken WestoverAssociate Professor of Biochemistry and Radiation Oncology, UT SouthwesternDirección de correo verificada de utsouthwestern.edu
Laurent MeijerDirección de correo verificada de manros-therapeutics.com
Peter K. SorgerHarvard Medical SchoolDirección de correo verificada de hms.harvard.edu
Stefan KnappUniversity of FrankfurtDirección de correo verificada de pharmchem.uni-frankfurt.de
Young-Tae ChangPOSTECHDirección de correo verificada de postech.ac.kr
Zachary Hunter, PhDDana-Farber Cancer Institute - Bing Center for WMDirección de correo verificada de dfci.harvard.edu
Ultan McDermottFaculty, Wellcome Trust Sanger InstituteDirección de correo verificada de sanger.ac.uk
John R. EngenJames L. Waters Chair & Distinguished Professor of Chemistry, Northeastern UniversityDirección de correo verificada de neu.edu
Mario NiepelRibon TherapeuticsDirección de correo verificada de ribontx.com
Elizabeth A. WinzelerProfessor, University of California San Diego, School of MedicineDirección de correo verificada de ucsd.edu
Badry BursulayaGNFDirección de correo verificada de gnf.org
Craig MermelProduct Lead for Pathology, Google AIDirección de correo verificada de google.com
Daniel LimMIT Koch InstituteDirección de correo verificada de mit.edu
Lyn JonesDana-Farber Cancer InstituteDirección de correo verificada de dfci.harvard.edu
Simon ArthurUniversity of DundeeDirección de correo verificada de dundee.ac.uk
Roxana IacobResearch Associate Professor, Northeastern UniversityDirección de correo verificada de neu.edu
Neal RosenProfessor of Pharmacology, Memorial Sloan-Kettering Cancer CenterDirección de correo verificada de mskcc.org
Gad GetzMassachusetts General Hospital and Broad Institute of Harvard and MITDirección de correo verificada de broadinstitute.org
Thorold W. TheunissenAssistant Professor of Developmental Biology at Washington University in St. LouisDirección de correo verificada de wustl.edu

Seguir

Nathanael Gray

Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Dirección de correo verificada de dfci.harvard.edu

medicinal chemistry cancer research structure-based drug design kinase inhibitors chemical biology


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Targeting cancer with small molecule kinase inhibitors J Zhang, PL Yang, NS Gray Nature reviews cancer 9 (1), 28-39, 2009	2944	2009
Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012	2259	2012
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, ... Journal of Biological Chemistry 284 (12), 8023-8032, 2009	1850	2009
A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017	1651	2017
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival TR Peterson, M Laplante, CC Thoreen, Y Sancak, SA Kang, WM Kuehl, ... Cell 137 (5), 873-886, 2009	1384	2009
A unifying model for mTORC1-mediated regulation of mRNA translation CC Thoreen, L Chantranupong, HR Keys, T Wang, NS Gray, DM Sabatini Nature 485 (7396), 109-113, 2012	1353	2012
A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016	1226	2016
Rational design of inhibitors that bind to inactive kinase conformations Y Liu, NS Gray Nature chemical biology 2 (7), 358-364, 2006	1185	2006
A chemical switch for inhibitor-sensitive alleles of any protein kinase AC Bishop, JA Ubersax, DT Petsch, DP Matheos, NS Gray, J Blethrow, ... nature 407 (6802), 395-401, 2000	1165	2000
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ... Clinical cancer research 14 (13), 4275-4283, 2008	1123	2008
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors NS Gray, L Wodicka, AMWH Thunnissen, TC Norman, S Kwon, ... Science 281 (5376), 533-538, 1998	1119	1998
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling PP Hsu, SA Kang, J Rameseder, Y Zhang, KA Ottina, D Lim, TR Peterson, ... Science 332 (6035), 1317-1322, 2011	1094	2011
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ... Nature 462 (7276), 1070-1074, 2009	1066	2009
Activating mutations in ALK provide a therapeutic target in neuroblastoma RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ... Nature 455 (7215), 975-978, 2008	916	2008
Systematic identification of culture conditions for induction and maintenance of naive human pluripotency TW Theunissen, BE Powell, H Wang, M Mitalipova, DA Faddah, J Reddy, ... Cell stem cell 15 (4), 471-487, 2014	754	2014
MEK1 mutations confer resistance to MEK and B-RAF inhibition CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, ... Proceedings of the National Academy of Sciences 106 (48), 20411-20416, 2009	703	2009
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate MG Sanna, J Liao, E Jo, C Alfonso, MY Ahn, MS Peterson, B Webb, ... Journal of Biological Chemistry 279 (14), 13839-13848, 2004	690	2004
The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015	679	2015
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ... Nature 511 (7511), 616-620, 2014	649	2014
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsResistance Mechanisms in ALK Kinase Inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011	630	2011

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores